ASTRO's 54th Annual Meeting CE Tracking Form This form is for your personal use only and is not the CE evaluation. Therefore, it cannot be submitted to earn credit. To earn credit, you must complete an online evalaution. Directions on how to access the evaluation by credit type are included below: CME: All registed full conference and full day physician attendees are eligible to earn CME credit. To earn CME credit you will need to complete the online meeting evaluation. The evaluation can be completed on site at the CE Central access stations (North Lobby, Level 1) or online from your hotel, home, or office up to 60 days post meeting using the following link: http://astro2012.expotrack.net. Please note that you will need to enter your badge number in order to complete the online evaluation, so please make note of this number if you plan on completing the evaluation postmeeting. Certificates of completion will be available on the ASTRO website 60 days post meeting. CAMPEP: All registed full conference and full day physicist attendees are eligible to earn CAMPEP credit. To earn CAMPEP credit you will need to complete the online meeting evaluation. The evaluation can be completed on site at the CE Central access stations (North Lobby, Level 1) or online from your hotel, home, or office up to 60 days post meeting using the following link: http://astro2012.expotrack.net. Please note that you will need to enter your badge number in order to complete the online evaluation, so please make note of this number if you plan on completing the evaluation post meeting. All completed evaluations will be submitted to CAMPEP within 60 days of the conclusion of the meeting. MDCB: All registed full conference and full day dosimetrist attendees are eligible to earn MDCB credit. To earn MDCB credit you will need to complete the online meeting evaluation. The evaluation can be completed on site at the CE Central access stations (North Lobby, Level 1) or online from your hotel, home, or office up to 60 days post meeting using the following link: http://astro2012.expotrack.net. Please note that you will need to enter your badge number in order to complete the online evaluation, so please make note of this number if you plan on completing the evaluation post meeting. All completed evaluations will be submitted to MBDC within 60 days of the conclusion of the meeting. ONS: SAM: All registered nurse and nurse practitioner attendees will receive an email with a link to an individualized ONS evaluation on Sunday, October 27, 2012. You will need to complete that ONS evaluation in order to earn ONS credit. All completed evaluations will be submitted to ONS within 60 days of the conclusion of the meeting. All registered full conference and full day physician and physicist attendees can earn SAM credit by pre registering ($35 per session) for one of the five Live SAM sessions. To earn credit, participants will need to answer all 13 of the required assessment and evlauation questions. Certificates of completion will be available on the ASTRO website 30 days post meeting. Need help? While on site, please stop by CE Central in the North Lobby, Level 1 to talk to staff from ASTRO's Education Department. Post meeting, please contact Lisa Cheak at LisaC@astro.org or 703 286 1572.
Sessions Approved for CE Credit Saturday, October 27, 2012 8:00 AM Econ1 Contouring for Esophageal Cancer 153 A C 1.50 1.50 1.50 n/a n/a 10:30 AM Econ2 Contouring for Lymphoma 153 A C 1.50 1.50 1.50 n/a n/a 1:00 PM Econ3 Contouring for Lung Cancer 153 A C 1.50 1.50 1.50 n/a n/a 3:30 PM Econ4 Contouring for Head and Neck Cancer I 153 A C 1.50 1.50 1.50 n/a n/a Sunday, October 28, 2012 8:00 AM Econ5 Contouring for Head and Neck Cancer II 153 A C 1.50 1.50 1.50 n/a n/a 8:10 AM PSI Session I: Why Innovation Grand Ballroom 0.25 0.17 0.25 n/a n/a 8:20 AM PSII Session II: The Promise of Innovation Grand Ballroom 1.50 1.50 1.50 1.50 n/a 10:15 AM PSIII Session III: Advancing Innovation in Radiation Oncology: Redesign, Repurpose, Restructure Grand Ballroom 1.00 1.00 1.00 1.00 n/a 10:30 AM Econ6 Contouring for Gynecological Cancer 153 A C 1.50 1.50 1.50 n/a n/a 11:00 AM Nursing1 When A Patient in Radiation has a Cardiac Device 204 A B 1.50 1.50 1.50 1.50 n/a 11:15 AM PSIV Session IV: Innovative Designs for Delivery of Radiation Oncology Care Grand Ballroom 1.00 1.00 1.00 1.00 n/a 12:15 PM PSV Lessons Learned Grand Ballroom 0.50 0.33 0.50 0.50 n/a 1:00 PM Econ7 Contouring for Gastrointestinal Cancer 153 A C 1.50 1.50 1.50 n/a n/a 1:45 PM EDU101 Difficult Cases in Breast Cancer 253 A C 1.50 1.50 1.50 1.50 n/a 1:45 PM EDU102 Challenging Cases of Hodgkin's Lymphoma and Non Hodgkin's Lymphoma 107 A C 1.50 1.50 1.50 1.50 n/a 1:45 PM PD01 Sarcoma/ Skin Cancer 156 A C 1.50 1.50 n/a n/a n/a 1:45 PM PD02 Lung 157 A C 1.50 1.50 n/a n/a n/a 1:45 PM SSA Clinical Trials and Innovative Care 210 A C 1.50 1.50 n/a n/a n/a 1:45 PM SSB CNS I Primary Brain Tumors 206 A B 1.50 1.50 n/a n/a n/a 1:45 PM SSC GI I Hypofractionated and Stereotactic Radiotherapy for Hepatic/Biliary/Pancreatic Tumors 259 A B 1.50 1.50 n/a n/a n/a 1:45 PM SSD GU I Prostate Cancer: Toxicity / Second Cancers 258 A C 1.50 1.50 n/a n/a n/a 1:45 PM SSE GYN I Cervical Cancer 254 A B 1.50 1.50 n/a n/a n/a 1:45 PM SSF Head and Neck I Target Delineation/Patterns of Failure 052 A B 1.50 1.50 n/a n/a n/a 1:45 PM SSG Biology I Biologic Prognostic/Predictive Factors 109 A B 1.50 1.50 n/a n/a n/a 1:45 PM SSH Physics I Adaptive RT 205 A C 1.50 1.50 n/a n/a n/a 3:30 PM Econ8 Contouring for Prostate Cancer 153 A C 1.50 1.50 1.50 n/a n/a 3:30 PM Nursing2 Bare Facts and Treatments Regarding Skin Toxicities 204 A B 1.50 1.50 1.50 1.50 n/a 4:15 PM EDU103 Pancreatic Cancer: Current treatment Approaches and Controversies 107 A C 1.50 1.50 1.50 1.50 1.00 4:15 PM EDU104 Radiation/Chemoradiation and Biological Targeting 254 A B 1.50 1.50 1.50 1.50 n/a 4:15 PM PAN01 The Role of Innovation in Breast Conservation Cure, Convenience and Cost 253 A C 1.50 1.50 1.50 1.50 n/a 4:15 PM PAN02 Innovative Approaches to the Management of Spinal Metastasis 052 A B 1.50 1.50 1.50 1.50 n/a 4:15 PM PAN03 Pareto Frontiers: Physician Driven Treatment Planning 210 A C 1.50 1.50 1.50 1.50 n/a 4:15 PM PAN04 Cancer Survivorship: Multidisciplinary Care of Patients After Treatment Completion 109 A B 1.50 1.50 1.50 1.50 n/a 4:15 PM PAN05 Impact of Genetic Factors, Autoimmunity and Comorbidity on Radiotherapy Toxicity 258 A C 1.50 1.50 1.50 1.50 n/a
Monday, October 29, 2012 8:00 AM EDU201 Optimal Sequencing of Radiotherapy and Types of Reconstruction Post Mastectomy 205 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU202 Role of Biologic Imaging in CNS Tumors 153 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU203 Challenging Cases in GI Malignancy 107 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU204 Management of High risk Prostate Cancer (Including Postoperative XRT) 258 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU205 Management of Oropharynx Cancer and Associated Toxicities 210 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU206 Historical Prospective of Pediatric Radiation Oncology; Particle Radiation Therapy and Combined Modality 206 A B 1.50 1.50 1.50 1.50 n/a for GI Malignancies 8:00 AM EDU207 Updated Roles and Rules for Radiation Therapy of Indolent and Aggressive Lymphomas 109 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU208 Cancer Emergencies 160 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU209 Radiobiology of Hypofractionation and IMRT 052 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU210 Image Guidance in the Treatment Room: Technology and Strategies 253 A C 1.50 1.50 1.50 1.50 n/a 9:45 AM KEYI The Real Cost of Healthcare Grand Ballroom 1.00 1.00 1.00 1.00 n/a 11:00 AM EDU211 Difficult Cases in Endometrial and Vaginal Cancer 253 A C 1.50 1.50 1.50 1.50 n/a 11:00 AM EDU212 Integration of Systemic Treatment With Radiation Therapy for Head and Neck Cancer 107 A C 1.50 1.50 1.50 1.50 1.00 11:00 AM PD03 Biology 156 A C 1.50 1.50 n/a n/a n/a 11:00 AM PD04 Genitourinary 157 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSI Best of Physics 210 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSJ Breast I Early Stage Local Therapy 205 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSK CNS II Low Grade, Benign and Spine 206 A B 1.50 1.50 n/a n/a n/a 11:00 AM SSL GI II Esophageal and Gastric: Understanding Toxicity Improving Outcomes 160 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSM Health Services Research I Clinical Trials and Guidelines 153 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSN Lung I SBRT: Efficacy/Response Assesment/Toxicity 052 A B 1.50 1.50 n/a n/a n/a 11:00 AM SSO Palliative Care/Quality of Life 109 A B 1.50 1.50 n/a n/a n/a 11:00 AM SSP Physics II Particle Therapy 258 A C 1.50 1.50 n/a n/a n/a 11:00 AM Nursing3 Role of the Advanced Practice Nurse (APN) in a Radiation Oncology Setting 259 A B 1.50 1.50 1.50 1.50 n/a 1:45 PM PresAddress Patient Not Treated Grand Ballroom 0.75 0.75 0.50 0.75 n/a 2:30 PM Plenary Plenary Session Grand Ballroom 1.25 1.25 n/a n/a n/a 4:00 PM EDU213 Cancer of the Colon, Rectum and Anus 258 A C 1.50 1.50 1.50 1.50 n/a 4:00 PM EDU214 Volumetric Modulated Arc Therapy: Planning and Quality Assurance 253 A C 1.50 1.50 1.50 1.50 n/a 4:00 PM PAN06 Post Mastectomy Radiotherapy After Neoadjuvant Chemotherapy: Update on Indications for Treatment 210 A C 1.50 1.50 1.50 1.50 n/a 4:00 PM PAN07 Innovations in Stereotactic Body Radiation Therapy for Lung Cancer 205 A C 1.50 1.50 1.50 1.50 n/a 4:00 PM PAN08 Brachytherapy Fundamentals and Evolving Paradigms 107 A C 1.50 1.50 1.50 1.50 1.00 4:00 PM PAN09 The Role of Innovation in Palliation Is the Benefit Worth the Cost? 160 A C 1.50 1.50 1.50 1.50 n/a 4:00 PM PAN10 Cancer Genesis, Treatment and Late Effects Across the Age Spectrum 153 A C 1.50 1.50 1.50 1.50 n/a Tuesday, October 30, 2012 8:00 AM EDU301 Breast Cancer Management: Early Stage Disease 258 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU302 Esophagus and Gastric Cancer: Contemporary Treatment Approaches 253 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU303 Controversies in the Management of Interactive Endometrial Cancer 107 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU304 Improving Outcomes in Geriatric Patients Through Use of Comprehensive Geriatric Assessment: Tools 153 A C 1.50 1.50 1.50 1.50 n/a Available to Make it Happen 8:00 AM EDU305 External Beam Radiotherapy for Prostate Cancer: Dose, Volume, Fractionation 205 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU306 Radiation Oncology in the Developing World How to Bridge the Gap 052 A B 1.50 1.50 1.50 1.50 n/a
8:00 AM EDU307 Pediatric Tumors: Update on Pediatric Sarcomas and Hodgkin Lymphoma 206 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU308 Soft Tissue and Bone Sarcoma Management of Difficult Cases 204 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU309 Cell Death Processes and Bystander Effects: Relevant to Clinical Radiotherapy 109 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU310 Practical Use of Image Registration and Data Fusion for Planning, Delivery and Adaptation of Radiotherapy 160 A C 1.50 1.50 1.50 1.50 n/a 1:15 PM EDU311 Advances in Treatment Planning for Prostate Cancers 253 A C 1.50 1.50 1.50 n/a n/a 1:15 PM EDU312 Low/High Grade Gliomas An Update 107 A C 1.50 1.50 1.50 1.50 1.00 1:15 PM Nursing4 Protons, Neutrons and Advanced Technologies in Radiation Therapy 206 A B 1.50 1.50 1.50 1.50 n/a 1:15 PM PD05 Breast 156 A C 1.50 1.50 n/a n/a n/a 1:15 PM PD06 Gastrointestinal 157 A C 1.50 1.50 n/a n/a n/a 1:15 PM SSQ GU II Prostate Cancer: Prognostic Factors 258 A C 1.50 1.50 n/a n/a n/a 1:15 PM SSR Head and Neck II Treatment Toxicity 052 A B 1.50 1.50 n/a n/a n/a 1:15 PM SSS Pediatrics I CNS 154 1.50 1.50 n/a n/a n/a 1:15 PM SST Lung II Biologics and Chemo/RT 160 A C 1.50 1.50 n/a n/a n/a 1:15 PM SSU Lymphoma Outcomes (Efficacy, Toxicity) and Innovations 153 A C 1.50 1.50 n/a n/a n/a 1:15 PM SSV Biology II Translational Radiobiology 109 A B 1.50 1.50 n/a n/a n/a 1:15 PM SSW Physics III Radiobiological Modeling 204 A B 1.50 1.50 n/a n/a n/a 1:15 PM SSX Physics IV IGRT Process and Technologies 205 A C 1.50 1.50 n/a n/a n/a 3:00 PM EDU313 Head and Neck Case Presentations 253 A C 1.50 1.50 1.50 1.50 n/a 3:00 PM EDU314 Radiation Oncology in the Era of Delivery System and Payment Reform 107 A C 1.50 1.50 1.50 1.50 n/a 3:00 PM Nursing 5 Adult Cancer Survivors: One Size Doesn't Fit All 153 A C 1.50 1.50 1.50 n/a n/a 3:00 PM PD07 Central Nervous System 156 A C 1.50 1.50 n/a n/a n/a 3:00 PM PD08 Physics SBRT Techniques 157 A C 1.50 1.50 n/a n/a n/a 3:00 PM SSAA GU III Prostate Cancer: High Risk / Androgen Deprivation / Metastatic PCA 258 A C 1.50 1.50 n/a n/a n/a 3:00 PM SSBB GYN II Endometrial, Vulvar, Vagina, Ovarian Cancer 109 A B 1.50 1.50 n/a n/a n/a 3:00 PM SSCC Health Services Research II Quality of Care 204 A B 1.50 1.50 n/a n/a n/a 3:00 PM SSDD Lung III Toxicity and Brain/PET 160 A C 1.50 1.50 n/a n/a n/a 3:00 PM SSEE Biology III Biodosimetry and Normal Tissue Radiobiology 254 A B 1.50 1.50 n/a n/a n/a 3:00 PM SSFF Physics V Tumor Imaging and Delineation 052 A B 1.50 1.50 n/a n/a n/a 3:00 PM SSY Breast II Treatment Techniques 205 A C 1.50 1.50 n/a n/a n/a 3:00 PM SSZ GI III Pancreatic Cancer 206 A B 1.50 1.50 n/a n/a n/a 4:45 PM EDU315 Hypofractionation in the Management of CNS Tumors 153 A C 1.50 1.50 1.50 1.50 n/a 4:45 PM EDU316 An Overview of Projection Imaging and Digital Concepts for Radiation Oncology 258 A C 1.50 1.50 1.50 1.50 n/a 4:45 PM PAN11 Quality Control of Lung SBRT: From 4D Simulation to 4D Verification 210 A C 1.50 1.50 1.50 1.50 n/a 4:45 PM PAN12 Innovative Clinical Trial Designs 253 A C 1.50 1.50 1.50 n/a n/a 4:45 PM PAN13 Patient Reported Outcomes: "Hearing the Patient's Voice" in a User friendly and Meaningful Way 109 A B 1.50 1.50 1.50 1.50 n/a 4:45 PM PAN14 Primer on Cost effectiveness Analysis in Radiation Oncology 107 A C 1.50 1.50 1.50 n/a n/a 4:45 PM PAN15 Tumor Metabolism and Radiation Response 160 A C 1.50 1.50 1.50 1.50 n/a Wednesday, October 31, 2012 8:00 AM EDU401 Challenging Cases in the Management of Newly Diagnosed and Recurrent Prostate Cancer 258 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU402 Management of Less Common Head and Neck Cancer Including Unknown Primary, Sinonasal Cancer and 205 A C 1.50 1.50 1.50 1.50 n/a Salivary Gland Cancer 8:00 AM EDU403 Difficult Cases in Cervical and Vulvar Cancer Management 107 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU404 Challenging Lung Cancer Cases 253 A C 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU405 Controversies on the Role of Radiation Therapy in the Management of Hodgkin Lymphoma (HL) 153 A C 1.50 1.50 1.50 1.50 n/a
8:00 AM EDU406 Integration of Safety in Quality Assurance Programs 109 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU407 ASTRO/PROS Session: Challenging Cases in Childhood Brain Tumors 206 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU408 Alpha Particle Therapy is Here: Incorporating Novel Radiopharmaceuticals into your Practice 204 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU409 Molecular Radiobiology Concepts and Clinical Applications 254 A B 1.50 1.50 1.50 1.50 n/a 8:00 AM EDU410 Advanced Treatment Technologies: Design, Control Systems, and Commissioning 210 A C 1.50 1.50 1.50 1.50 n/a 9:45 AM KEYIII Value Based Healthcare Delivery Grand Ballroom 1.00 1.00 1.00 1.00 n/a 11:00 AM EDU411 Advanced Treatment of Non Small Cell Lung Cancer: Using All the Tools (Imaging, Motion Correction, and 107 A C 1.50 1.50 1.50 1.50 1.00 IMRT) Promises and Pitfalls A Case Based Approach 11:00 AM EDU412 Interstitial Brachytherapy for Prostate Cancer: LDR and HDR, Alone and with External Beam Radiotherapy 258 A C 1.50 1.50 1.50 1.50 n/a 11:00 AM PD09 Head and Neck 156 A C 1.50 1.50 n/a n/a n/a 11:00 AM PD10 Quality of Life 157 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSGG Breast III Locally Advanced/New Modalities 205 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSHH CNS III: Metastases 109 A B 1.50 1.50 n/a n/a n/a 11:00 AM SSII GU IV Bladder Cancer/Kidney Cancer/Seminoma 204 A B 1.50 1.50 n/a n/a n/a 11:00 AM SSJJ Health Service Research III Large Population based and Decision Analysis 153 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSKK Biologic Radiosensitizers I 206 A B 1.50 1.50 n/a n/a n/a 11:00 AM SSLL Patient Safety and Quality Assurance 253 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSMM Emerging Technologies and Concepts 210 A C 1.50 1.50 n/a n/a n/a 11:00 AM SSNN Sarcoma and Cutaneous Tumors 254 A B 1.50 1.50 n/a n/a n/a 1:30 PM EDU413 Stereotactic Body RT: Clinical, Biological and Physics/QA Update 253 A C 1.50 1.50 1.50 1.50 n/a 1:30 PM EDU414 Cervical Cancer Management : Novel approaches to Image Guidance 107 A C 1.50 1.50 1.50 1.50 n/a 1:30 PM PD11 IGRT Technologies and Processes 156 A C 1.50 1.50 n/a n/a n/a 1:30 PM SSOO Breast IV Prognostic Factors 258 A C 1.50 1.50 n/a n/a n/a 1:30 PM SSPP GI IV GI Cancer from the Bottom to the Top with an Emphasis on Rectal Cancer 153 A C 1.50 1.50 n/a n/a n/a 1:30 PM SSQQ GU V Prostate Cancer: Hypofractionation / Brachytherapy 254 A B 1.50 1.50 n/a n/a n/a 1:30 PM SSRR Head and Neck III Reirradiation/Quality Assurance 205 A C 1.50 1.50 n/a n/a n/a 1:30 PM SSSS Lung IV Fractionation and Toxicity 210 A C 1.50 1.50 n/a n/a n/a 1:30 PM SSTT Informatics/Bioinformatics 109 A B 1.50 1.50 n/a n/a n/a 1:30 PM SSUU Pediatrics Non CNS Tumors 206 A B 1.50 1.50 n/a n/a n/a 1:30 PM SSVV Biologic Radiosensitizers II 204 A B 1.50 1.50 n/a n/a n/a 3:15 PM EDU415 ASTRO Highlights in Spanish 204 A B 1.50 1.50 1.50 n/a n/a 3:15 PM EDU416 Treatment Option for Patients with Early stage Non small Cell Lung Cancer 258 A C 1.50 1.50 1.50 1.50 n/a 3:15 PM PAN16 Hypofractionation Dose Response Models for SRS, SBRT, FSRT: Biology, Physics and Clinic 210 A C 1.50 1.50 1.50 1.50 n/a 3:15 PM PAN17 Linac based Image Guidance for Spatial and Dosimetric Treatment Verification 253 A C 1.50 1.50 1.50 n/a n/a 3:15 PM PAN18 Evidence Based Management of Testicular Seminoma, Stage I and II 254 A B 1.50 1.50 1.50 1.50 n/a 3:15 PM PAN19 Multi modality Approach to the Management of Liver Malignancy and Metastasis 107 A C 1.50 1.50 1.50 1.50 n/a 3:15 PM PAN20 Biological Controversies and How They Impact Conventional Radiotherapy 153 A C 1.50 1.50 1.50 1.50 n/a